HDM1005
GIP/GLP-1 · s.c. · Huadong Medicine
Summary
- Also known as
- Huadong
- Mechanism
- GIP/GLP-1
- Route
- s.c.
- Company
- Huadong Medicine
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 in China (obesity; T2D; head-to-head vs mazdutide in T2D) since Oct 2025; phase 2 T2D (20 wk) at EASD 2026: HbA1c up to −2.57 % verify
- Next milestone
- Phase 3 obesity results (primary completion Sep 2026)
Sources for the status
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Efficacy and Safety of HDM1005 Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial. ClinicalTrials.gov identifier NCT07279194. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07279194
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. A Multicenter, Randomized, Open-label, Parallel-controlled, Phase 3 Study to Compare the Efficacy and Safety of HDM1005 Versus Mazdutide in Subjects With T2DM Inadequate Glycemic Control by Metformin Monotherapy or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ClinicalTrials.gov identifier NCT07417306. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07417306
- Linong Ji et al. A phase 2 trial of HDM1005 in participants with type 2 diabetes not controlled with diet/exercise or metformin. Abstract 782. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: SO 068 Gut hormones, nutrients and metabolic effects]
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| T2D | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Phase II (obesity, non-diabetic) | 2.0 mg | obesity china | 22 | 243 | — | —−13.3 % vs −2.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| China Phase II (obesity, non-diabetic) | 4.0 mg | obesity china | 22 | 243 | — | —−13.3 % vs −2.5 % estimand not specified | — | — | — | — | — | — | — | press release |
| HDM1005 phase 2 (T2D) | HDM1005 3.0 mg | t2d china | 20 | 220 | −5.9 % vs −0.2 % Δ −5.7 pp | — | −2.6 vs −0.6 | — | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (4)
- HDM1005 3.0 mg · weight_eff · Abstract, Results
Dose-dependent body weight reductions were observed (LSM percentage change: -2.53%, -5.10%, -5.45%, -5.89% vs - 0.17% for placebo)
- HDM1005 3.0 mg · hba1c · Abstract, Results
the least squares mean (LSM) changes in HbA1c were -1.95%, -2.40%, -2.45%, and -2.57% for HDM1005 0.5, 1.0, 2.0, and 3.0 mg groups
- 2.0 mg · weight_unsp · secondary
2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%
- 4.0 mg · weight_unsp · secondary
2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%
Registered trials (5)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07794397 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy | Sleep apnoea | Phase 3 | not yet recruiting | 2026-09 → 2028-09 | 200 | not yet recruiting | NCT07794397 |
| NCT07787260 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy | Sleep apnoea | Phase 3 | not yet recruiting | 2026-08 → 2028-03 | 200 | not yet recruiting | NCT07787260 |
| NCT07417306 A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | T2D | Phase 3 | not yet recruiting | 2026-03 → 2027-08 | 912 | not yet recruiting | NCT07417306 |
| NCT07394114 A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | T2D | Phase 3 | recruiting | 2026-02 → 2027-08 | 240 | recruiting | NCT07394114 |
| NCT07279194 · China Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes | Obesity | Phase 3 | recruiting | 2025-10 → 2026-09 | 825 | recruiting | NCT07279194 |
Primary sources
- Linong Ji et al. A phase 2 trial of HDM1005 in participants with type 2 diabetes not controlled with diet/exercise or metformin. Abstract 782. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: SO 068 Gut hormones, nutrients and metabolic effects]
- Huadong Medicine. 华东医药HDM1005注射液减重II期临床告捷 (Pharnexcloud news, Chinese) [secondary]. 2025-12-15. Available from: https://www.pharnexcloud.com/zixun/shiye/lcyj_261317
How to cite this page
Cite the primary publication for any single result; every value above links to it.